ORIGINAL RESEARCH Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials Pedro L. Gonzalez . Urania Rappo . Karthik Akinapelli . Jennifer S. McGregor . Sailaja Puttagunta . Michael W. Dunne Received: April 16, 2021 / Accepted: November 12, 2021 Ó The Author(s) 2021 ABSTRACT Introduction: Dalbavancin is a long-acting, bactericidal, lipoglycopeptide antibiotic approved by the US Food and Drug Adminis- tration and the European Medicines Agency for treatment of acute bacterial skin and skin structure infections in adults, with potent activity against Gram-positive pathogens, including methicillin-susceptible and methi- cillin-resistant Staphylococcus aureus. Here we describe the clearance and clinical outcomes of patients with S. aureus bacteremia in five clinical trials of skin and skin structure infections or catheter-related bloodstream infections that evaluated the efficacy and safety of dalba- vancin. Methods: Patients with uncomplicated S. aureus bacteremia identified in blood cultures drawn at baseline (before study drug) with at least one follow-up blood culture are described from four phase 3 trials in skin and skin structure infec- tions and one phase 2 catheter-related infection study. Dalbavancin was administered as a sin- gle-dose (1500 mg intravenous [IV]) or a two- dose regimen (1000 mg IV on day 1, 500 mg IV on day 8). Comparators included vancomycin IV or linezolid IV/oral for 10–14 days. Results: All 39 patients (100%) who received dalbavancin, including 8 patients on the single- dose regimen, had clearance of bacteremia ver- sus 19/20 patients (95%) treated with com- parators (vancomycin or linezolid). At end of treatment, 33/36 dalbavancin-treated patients (92%) achieved clinical success versus 18/23 patients (78%) treated with comparators. Conclusions: All 39 patients with uncompli- cated S. aureus bacteremia treated with dalba- vancin (single- or two-dose regimen) and with follow-up blood cultures had clearance of their bloodstream infection. Clinical response rates Pedro L. Gonzalez and Urania Rappo contributed equally to the work. P. L. Gonzalez (&) Á S. Puttagunta Á M. W. Dunne Infectious Disease Medical Affairs and Internal Medicine, AbbVie, Madison, NJ, USA e-mail: papitin@yahoo.com U. Rappo Clinical Development, Infectious Diseases, AbbVie, Madison, NJ, USA K. Akinapelli Á J. S. McGregor Medical Affairs Infectious Diseases, AbbVie, Madison, NJ, USA Present Address: P. L. Gonzalez Becton-Dickinson, 1 Becton Dr, Franklin Lakes, NJ 07417-1880, USA Present Address: U. Rappo Á S. Puttagunta BiomX Inc., Branford, CT, USA Present Address: K. Akinapelli Á M. W. Dunne Iterum Therapeutics, Old Saybrook, CT, USA Infect Dis Ther https://doi.org/10.1007/s40121-021-00568-7